Early-phase Study Shows Shrinkage in Pediatric Neural Tumors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, in most cases, responded to it with tumor shrinkage. NF1 affects one in 3,000 people.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Researchers at Baylor College of Medicine and Texas Children’s Cancer Center were awarded more than $7.6 million over four years from NCI to comprehensively study late effects of childhood cancer in a diverse population of childhood cancer survivors, including their medical, neurocognitive, and psychosocial outcomes. In addition, they will evaluate potential educational and sociodemographic barriers to obtaining survivorship care.

Login